Add this topic to your myFT Digest for news straight to your inbox
Technique devised for Timothy syndrome could open way to therapies for other untreatable conditions
Technique highlights concerns shifting global disease burden as populations age
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval
Xi Jinping hopes manufacturing can offset the property slump
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Research harnesses power of generative artificial intelligence in latest sign of its potential use in medicine
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
UK research highlights risk of over-diagnosis and gaps in spotting serious variants of the disease
The idea that the technology might accelerate general human capabilities remains fanciful
Growing number of countries are also considering whether to amend legislation
US healthcare company is putting cash to work from spinning off its consumer health arm
Research forecasts global deaths from the disease will almost double in 20 years
Outbreak kills at least one baby and is likely to worsen based on Dutch data
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
WHO member states are struggling to agree the terms of the first global treaty to deal with the threat of another Covid-19
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Widespread testing for this treatable if embarrassing condition is being hampered by lack of access to healthcare
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Chemotherapy can target microscopic cells to prevent the disease from spreading
International Edition